Author:
Drogovoz S. M.,Kalko K. O.,Bondarev Ye. V.,Belik G. V.,Stoletov Yu. V.,Derimedvid L. V.
Abstract
Drugs which as we hope, have to facilitate or save the patient's life sometimes cause the return ˗ the collateral reactions (CR) and even death. CR of drugs can be a cause of death not less, than sepsis and accidents. Often the wrong dispensing and also the medicines prescribed by off label is their reason (out of the instruction). The aim of the study. To analyze the frequency of manifestation of collateral reactions of medicines at their application of off label. Materials and methods. The analysis of foreign and domestic scientific publications concerning manifestation of collateral reactions of drugs at their application off label. Results. Today there are no concrete data on that how many deadly CR happen because of off label of drugs, but it is possible to estimate it, using information which is known: CR at drug intake of off label occur approximately by two-three times more often than at drug intake of on label (according to the instruction). It is established that lower or higher dose of medicine, than that which is specified in the instruction can lead to security concerns. Use of off label of medicines in doses is higher than those which were approved by the instruction, correlate with increase in risk of development of CR. It is established that prescription of medicines of off label is connected with higher risk of CR, than with their licensed alternatives, and hypotheses in literature concerning efficiency and harmlessness of off label of use of drugs not always are reliable. Conclusions. The doctor and the pharmacist need to remember that positive effects of application of off label of drugs have to have synergism with their safety that the medicine off label, very necessary for the patient, did not appear without the obligatory quality ˗ safety.
Publisher
LLC Information and Research Center Likarska Sprava
Reference28 articles.
1. Drogovoz S. M. Farmakologiya v pomoshch' vrachu, provizoru i studentu. – H.: Titul, 2018. – 640 p.
2. Drogovoz S. M., Matveeva E. V., Lukiyanchuk Yu. O., Rakeev P. V. Faktory, sposobstvuyushchie pobochnym effektam off label preparatov // Farmakologіya ta lіkars'ka toksikologіya. – 2018. – № 2. – P. 92–96. –http://nbuv.gov.ua/UJRN/flt_2018_2_12
3. Pobochnoe dejstvie lekarstv (logika bezopasnosti lekarstv): Uch.-sprav. / Pod red. S. M. Drogovoz. – H.: SIM, 2010. – 480 p.
4. Chernyh V. P., Drogovoz S. M., Zupanec I. A. i dr. Karboksiterapiya – stil' off label use (lekarstvennye sredstva vne instrukcii) // Lіk. sprava=Vracheb. delo. – 2017. – № 5–6. – P. 112–116.
5. Aagaard L., Hansen E. H. Prescribing of medicines in the Danish paediatric population outwith the licensed age group: Characteristics of adverse drug reactions // Br. J. Clin. Pharmacol. – 2011. – Vol. 71, N 5. – P. 751–757.